ClinicalTrials.gg
RecruitingNCT07403630IT-TCP POSUpdated Feb 17, 2026

INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)

An interventional study of Functional tests and Multi-omics analyses in Acute Leukemia, Multiple Myeloma and Squamous Cell Carcinoma, sponsored by Azienda Ospedaliero-Universitaria di Parma. Recruiting at 2 sites in Italy. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Azienda Ospedaliero-Universitaria di Parma · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled May 2023, registered Feb 2026).
  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 286 studies in Multiple Myeloma with a site in Italy — 56 open to participants now, 98 under way, 43 of them phase 3. Multiple Myeloma · Italy.

Planned enrollment
84th of 227
300 · median 168
Started
2023
with 17 others
No phase
8 of 286
3 open now
Primary completion
2027-02
later than 42 of 97 live
Registered
272nd of 286
by date

Among the 286 studies in Multiple Myeloma with a site in Italy, this one is the 84th largest by planned enrollment of the 227 interventional ones that give a count, is one of 18 that started in 2023, is one of 8 with no phase, reaches primary completion later than 42 of the 97 other live ones, and was the 272nd registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

56 of the 286 studies in Multiple Myeloma with a site in Italy are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 286 studies in Multiple Myeloma with a site in Italy, or all of them as a file.
02

Study summary

This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk. The study will be prospective, based on the consecutive enrollment of eligible patients at each participating institution.

Read the detailed description

This pre-clinical, experimental study will involve primary samples from patients diagnosed with haematological or solid neoplasms defined as high-risk.

It will be prospective, based on consecutive enrolment of eligible patients at each participating institution. Patients will be enrolled based on their biological and clinical characteristics at the time of diagnosis. This will include patients with metastatic disease, as well as those with recurrent or refractory disease, particularly where the therapeutic indication is not supported by internationally recognised guidelines.

03

Conditions studied

  • Acute Leukemia
  • Multiple Myeloma
  • Squamous Cell Carcinoma
  • Pleural Mesothelioma
  • Pancreatic Cancer
  • Bladder Cancer
  • Ovarian Cancer
  • Melanoma
  • Pediatric Acute Lymphoblastic Leukemia
  • Chronic Leukemia
  • Myeloproliferative Disorders
  • Myelodysplastic Disorders
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged one year and over who are referred to the centres involved in the protocol (Azienda Ospedaliero-Universitaria di Parma, University of Parma, University of Perugia and Azienda Ospedali Riuniti Villa Sofia-Cervello of Palermo).
  • Patients with an established diagnosis of haematological or solid organ , including haematological or solid malignancies characteristic of the paediatric age group.
  • Patients diagnosed with , refractory and/or haematological or solid malignancy. Patients may be enrolled regardless of the extent and type of previous therapy. Patients may also be enrolled if they are undergoing active treatment at the time of evaluation.
  • Patients must have the capacity to understand the investigative nature of the study and provide in writing. For patients under the age of 12 years, consent will be provided by the parent/legal guardian according to international guidelines. For patients aged 12 to 17 years, consent will be provided by the patient and the parent/legal guardian according to the mature minor principle.

Exclusion criteria

Exclusion criteria:

  • Patients younger than 1 year old
  • Patients with active, uncontrolled infections
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Other
    Haematological neoplasms or neoplasms of solid organs

    * Patients with a confirmed diagnosis of hematological malignancy or solid organ malignancy, including solid or hematological malignancies characteristic of pediatric age. * Patients diagnosed with hematological or solid neoplasms defined as high risk, according to biological and clinical characteristics, including metastatic cases, or diagnosed with recurrent and/or refractory hematological or solid neoplasms.

    Biological: Functional tests · Other: Multi-omics analyses · Genetic: Cytogenetics/ FISH

Interventions

  • BiologicalFunctional tests

    Functional analyses will be performed on primary sample from each enrolled patient. Malignant cells are cultered and incubated with a specific library of drugs (300 drugs) at four different concentrations for 72 hours.

  • OtherMulti-omics analyses

    Our scientific approach is based on various investigations, including radiomics, digital pathology, immune profiling, bulk transcriptomics, single-cell resolution, single-cell transcriptomics, phosphoproteomics, functional immunoprofiling, and inflammasome analysis, NGS (Next Generation Sequencing analysis).

  • GeneticCytogenetics/ FISH

    Individual biopsy samples will be evaluated in a pipeline that includes established diagnostic elements, e.g., cytogenetics and FISH.

06

What researchers measure

Primary outcomes

  1. Evaluation of the rate of change in therapeutic indication of disease from standard-of-care.

    Time frame: At baseline

Secondary outcomes

  1. Evaluation of the possible use of the IT-TCP platform on the clinical level

    Time frame: At baseline

  2. Creation of an IT platform to store and manage the data generated

    Time frame: At baseline

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Feb 2027, 45 months after the start.

Of 172 non-industry interventional studies with no phase under Multiple Myeloma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 81. This study's planned 45 months is above that.

Counting every sponsor, half of 186 studies reached it within 38 months; a quarter within 20 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 11, 2026
StartActual
May 31, 2023
Primary completionEst.
Feb 2027
CompletionEst.
Feb 12, 2028
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07403630
Lead sponsor
Azienda Ospedaliero-Universitaria di Parma
Responsible party
Giovanni Roti (Full Professor, University of Parma) — Principal investigator
First posted
Feb 11, 2026
Start date
May 31, 2023
Primary completion
Feb 2027 (estimated)
Completion
Feb 12, 2028 (estimated)
Last update
Feb 17, 2026

Study contacts

Giovanni Roti, Associate Professor
Contact
giovanni.roti@unipr.it
+39 0521 702200

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion